benserazide has been researched along with Psychomotor Agitation in 5 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Psychomotor Agitation: A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5%, probably reflecting some differences in the bioavailability of the various galenical formulations, and the mean daily drug intakes were reduced from 5." | 2.68 | Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group. ( Gachoud, JP; Gasser, U; Ghika, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gershteĭn, LM | 1 |
| Tatarintseva, IM | 1 |
| Rakhmanova, VI | 1 |
| Linazasoro, G | 1 |
| Martí Massó, JF | 1 |
| Suárez, JA | 1 |
| Ghika, J | 1 |
| Gachoud, JP | 1 |
| Gasser, U | 1 |
| Schlosberg, AJ | 1 |
| Harvey, JA | 1 |
| van Rossum, JM | 1 |
1 review available for benserazide and Psychomotor Agitation
| Article | Year |
|---|---|
Two types of dopamine receptors in behavioral regulation.
Topics: Animals; Behavior; Behavior, Animal; Benserazide; Brain; Carbidopa; Cats; Dopamine; Haloperidol; Hum | 1978 |
1 trial available for benserazide and Psychomotor Agitation
| Article | Year |
|---|---|
Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bensera | 1997 |
3 other studies available for benserazide and Psychomotor Agitation
| Article | Year |
|---|---|
[Morphological and chemical reorganizations in parietal cortical neurons in conditions of hyperactivity of the dopaminergic system].
Topics: Animals; Benserazide; Cell Nucleus; Cytoplasm; Dopamine; Dopamine Agents; Drug Combinations; Levodop | 2010 |
Nocturnal akathisia in Parkinson's disease: treatment with clozapine.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Carbidopa; Circadian Rhythm; Clozapine; Confusion; Dose | 1993 |
Effects of L-dopa and L-5-hydroxytryptophan on locomotor activity of the rat after selective or combined destruction of central catecholamine and serotonin neurons.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Body Weight; Catecholamines; Humans; Levodopa; Locomotion | 1979 |